| |
|
|
|
The Boston Park Plaza Hotel and Towers, Boston, MA
March 26 - 27, 2007
• Foundational Technology
• Protein Engineering
• Metabolic Engineering
• Therapeutic Engineering
• Cellular and Tissue Engineering
• Government, Business and Regulatory Issues
|
|
|
|
|
|
|
|
Organized by:
|
|
IBC Life Sciences |
|
|
Invited Speakers:
|
|
Noubar B. Afeyan, Ph.D., Flagship Ventures
Jeffrey Chabot, Ph.D., Pfizer
J. J. Collins, Ph.D., Boston University
John Danner, Ph.D., Codon Devices, Inc.
Richard Fisler, President, Beachhead Consulting
David de Graaf, Ph.D., Pfizer RTC
Timothy S. Gardner, Ph.D., Boston University
J. Keith Joung, M.D., Ph.D., Harvard Medical School
John Karanicolas, Ph.D., University of Washington
E. M. Leproust, Ph.D., Agilent Technologies
Jan Liphardt, Ph.D., University of California, Berkeley
Jeremy Minshull, Ph.D., DNA 2.0
John Mulligan, Ph.D., Blue Heron Biotechnology, Inc.
Jack D. Newman, Ph.D., Amyris Biotechnologies, Inc.
Kristalla L. Jones Prather, Ph.D., Massachusetts Institute
of Technology
Enrico Picozza, Ph.D., Vector Objects
James R. Prudent, Ph.D., EraGen Biosciences, Inc.
Anthony Salerno, Ph.D., Agilent Technologies
Gary Sams, Ph.D., Chief Executive Officer, Beachhead
Consulting
David Schaffer, Ph.D., University of California, Berkeley
Pamela Silver, Ph.D., Harvard University
Christina D. Smolke, Ph.D., California Institute of
Technology
Cara Tracewell, Ph.D., California Institute of Technology
Christopher A.Voigt, Ph.D., University of California,
San Francisco
Ronald Weiss, Ph.D., Princeton University
|
|
|
|
|
|
|
|
Deadline for Abstracts:
|
|
|
|
|
|
|
|
|
|
Registration:
|
|
|
|
|
E-mail:
|
|
postings@ibcusa.com
|
|
|
|
|
|
|
|
|